Dual Immunotherapy Promising New Option for Liver Cancer

The combination of durvalumab plus the experimental drug tremelimumab significantly improved overall survival as compared to sorafenib.
Medscape Medical News

source https://www.medscape.com/viewarticle/967077?src=rss